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Abstract 
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous 
system. Gender influences both susceptibility to MS, with the disease being more common in 
women, and the clinical course of disease, with an increased proportion of males developing 
the primary progressive form of the disease. The basis for these differences may include 
genetic and immunological factors, and the immunological differences between men and 
women may be influenced by the effects of the sex hormones. Over several years we have 
collected blood from MS patients and controls, and measured T-cell responses to myelin 
proteolipid protein (PLP) and myelin basic protein (MBP) and have shown increased 
responses to PLP in MS patients compared to healthy controls and patients with other 
neurological diseases. In the present study we analyzed data from over 500 individuals, to 
determine whether there are differences between males and females in their responses to PLP 
and MBP. We found that there was higher frequency of increased T-cell reactivity to 
immunodominant PLP peptides in women than in men, particularly in non-MS individuals. 
We suggest that this may be relevant to the higher prevalence of MS in women.  
 
1. Introduction 
Many studies have shown that potentially autoreactive T and B cells can be found in the 
blood of healthy individuals [1, 2, 3, 4, 5, 6, 7, 8 and 9]. It is thought that these cells are kept 
in check by peripheral tolerance mechanisms, and that people who are susceptible to 
autoimmunity might have defects in these tolerance mechanisms, allowing the activation of 
the autoreactive cells and the development of pathogenic autoreactivity [10, 11, 12, 13 and 
14]. Autoreactive T cells and antibodies directed against central nervous system (CNS) 
antigens, particularly the components of myelin or oligodendrocytes [15, 16 and 17], have 
been implicated in the pathogenesis of multiple sclerosis (MS), a relatively common disorder 
causing significant neurological disability [18]. MS frequently affects young adults causing 
diverse neurological symptoms and signs including visual impairment, weakness and 
numbness, loss of balance and bladder disturbance [19]. 
We and others have found significantly increased T-cell reactivity to myelin proteolipid 
protein (PLP) [5, 20, 21, 22 and 23]in patients with MS compared to controls and compared 
to patients with other neurological disorders. In addition, we have shown that surges in the 
frequency of circulating T cells specific for PLP correlates with inflammatory CNS disease 
activity assessed by magnetic resonance imaging (MRI) in some MS patients [5]. There are 
also reports of increased T-cell reactivity to myelin basic protein (MBP) [24, 25 and 26], 
although we and others have not been able to confirm this [9, 20, 27 and 28], and to myelin 
oligodendrocyte glycoprotein (MOG) [28]. We and others have also found increased T- or B-
cell reactivity to gangliosides [29, 30, 31 and 32]. 
It is generally found that MS is more prevalent in females than in males, with a ratio of 
approximately 2:1. Our studies have been carried out in Queensland, Australia, where a 
detailed prevalence study of 420 MS subjects showed the ratio of females to males was 2.30:1 
[33]. As MS is thought to be an autoimmune disease, it is possible that the effects of gender 
on MS reflect differences in immune function. Indeed, many autoimmune diseases other than 
MS are more prevalent in women than in men. Using blood from MS patients and controls, 
we have performed studies of reactivity of T cells to MBP and PLP over a number of years, 
with the same two people performing the assays, using the same antigens and the same 
techniques. Because of the interest in possible gender differences in the immune response, we 
have analyzed our data from over 500 subjects on human T-cell responses to MBP and PLP 
with respect to gender, and show that increased T-cell reactivity to PLP is more frequent in 
women than in men, particularly in people who do not have MS. If PLP is indeed a target of 
pathogenic T cells and antibodies in MS, then this finding might be relevant to the higher 
prevalence of MS in women. 
2. Methods 
2.1. Subjects 
At different times over a 9 year period, subjects were recruited for studies of anti-myelin and 
anti-ganglioside activity in MS and for a study of T-cell responses to myelin and ganglioside 
antigens in patients with Guillain-Barré syndrome (GBS). In total, blood was collected from 
170 subjects with clinically definite or laboratory-supported definite MS, as defined by the 
criteria of Poser et al. [34], from 157 healthy subjects, and from 189 patients with other 
neurological diseases. MS patients had not received corticosteroid or other 
immunomodulatory therapies for at least 2 months prior to being studied, except for one 
patient who ceased interferon (IFN)-  therapy 5 weeks before being studied. The other 
neurological disease patients included 72 patients with other, non-immune-mediated CNS 
diseases, 59 patients with non-immune-mediated peripheral neuropathies and 58 patients with 
GBS. Within the 9 year timeframe, two distinct groups, each containing MS patients and 
healthy controls, were recruited (Group 1 and Group 2), and the results are presented for these 
groups both individually and as a whole for PLP. For MBP, reactivity in the two groups was 
almost identical, and therefore the results for the whole group only are shown. The patients 
with other non-immune-mediated CNS disease were mostly recruited at the same time as the 
MS and healthy control subjects in Group 1. Patients with other non-immune peripheral 
neuropathies or with GBS were mostly recruited at the same time as the MS and healthy 
control subjects in Group 2. 
2.2. T-cell proliferation 
All T-cell proliferation studies have been performed by the same two people (JMG and PAC), 
with no alterations in the methods. The T-cell proliferation assays were performed using 
established techniques on fresh peripheral blood mononuclear cells (PBMC), as previously 
described [20]. Briefly, PBMC were separated from heparinized blood by centrifugation 
through histopaque (Sigma Chemical Co, St Louis, USA) and washed twice. The in vitro 
responses of PBMC were assayed in triplicate or quadruplicate in 96-well round-bottomed 
microtitre plates. One hundred and fifty thousand PBMC and medium (RPMI 1640 containing 
10% heat-inactivated pooled human serum, 2 mM -glutamine, 10 mM HEPES buffer and 50 
M 2-mercaptoethanol) with or without peptides were added to wells in a total volume of 200 
l. PLP peptides 184–199 (QSIAFPSKTSASIGSL) and 190–209 
(SKTSASIGSLCADARMYGVL) were synthesized by Auspep (Melbourne, Australia) 
according to the human sequence of PLP and were >95% pure. Whole MBP was prepared 
from human brain tissue according to the method of Deibler et al. [35]. MBP peptide 82–100 
(DENPVVHFFKNIVTPRTPP—numbered according to the sequence of the 18.5 kDa isoform 
of human MBP) was synthesized at the Queensland Institute of Medical Research (Brisbane, 
Australia) and was >90% pure. Cultures were incubated for 6 days, with 0.5 Ci [3H]-
thymidine being added during the last 18 h. Cultures were harvested and thymidine uptake 
was measured in cpm (counts per min) in a -plate counter (LKB). Stimulation indices (SI) 
were determined by the formula: SI=(mean counts per min of peptide-containing 
wells)/(mean counts per min of control wells without peptide). 
2.3. Statistical analyses 
Chi-square analysis was used to compare the frequencies of patients and controls responding 
to antigens with SI≥2.0 and SI≥3.0. Yates' correction was applied when the number of 
positive samples in any test was 5 or less. Odds ratios (OR) and 95% confidence intervals 
(CI) of the OR for frequencies of responders in various groups were also calculated.  
3. Results 
3.1. Reactivity to PLP peptides is increased in MS patients 
compared to controls 
Previously we and others have shown that peptides PLP184–199 and PLP190–209 are 
immunodominant epitopes of PLP in human subjects [20 and 36]. Furthermore, these peptides 
are promiscuous in their ability to bind to a variety of MHC class II molecules, including 
those most commonly found in Caucasian populations (HLA DR2, DR3, DR4, DR5, DR6 and 
DR7). Thus, these peptides have the potential to be presented by HLA molecules found in 
most of the individuals included in this study. Table 1shows the reactivity to these PLP 
peptides by the different cohorts of subjects. The percentage of MS patients in Group 1 
responding with a SI≥3.0 to the PLP peptides (28.0%) was significantly greater than the 
percentages of Group 1 healthy controls (6.8%; P=0.0005) or patients with non-immune CNS 
diseases (11.1%; P=0.007) (Table 1). In Group 2, the second cohort of MS patients tested for 
reactivity to PLP peptides, there is a similar pattern of responses as in Group 1, with an 
increase in the frequencies of MS patients responding to PLP184–199 or PLP190–209 with a 
SI≥3.0 (16.8%) compared to healthy controls (7.1%; P=0.05) and patients with non-immune-
mediatedperipheral neuropathies (0%; P=0.01). However, in Group 2, the frequency of 
responders in the MS group was decreased compared to responders in Group 1. Since MS 
patients in Group 1 and Group 2 represented two distinct patient sets, we investigated possible 
reasons for the reduced responses in Group 2. We have previously reported that the 
proportion of MS patients making increased T-cell responses to PLP184–199 and PLP190–
209 is low in the early stages of MS (duration <6 years) and in patients who have had MS for 
more than 20 years, whereas more patients who have had MS for between 6–20 years have 
increased reactivity to these PLP peptides [20]. When the groups were analyzed according to 
disease duration, the highest percentages of responders were found in the groups of patients 
who had had MS for 10–20 years, and the lowest percentages of responders were those 
individuals who had had MS for <2 years or >20 years ( Fig. 1). When analyzed in this 
manner, the percentage of patients in Group 2 who had had MS for <2 years or >20 years and 
responded with an SI≥2.0 to PLP peptides was significantly less than the percentage of 
patients with the same disease duration from Group 1 (P=0.044), but there were no significant 
group differences between the results for patients with other disease durations or for the 
percentages of patients responding with an SI≥3.0.  
Table 1. Reactivity to PLP184–199 or PLP190–209 in patients with MS or control groups 
 
 Fig. 1. Effect of disease duration on T-cell reactivity to immunodominant PLP peptides in patients with 
MS. Apart from the SI≥2.0 response by patients in Group 2 with disease duration of <2 or >20 years 
(*), which was significantly decreased compared to the response by the corresponding population in 
Group 1 (P=0.044), there were no statistically significant differences between the two groups.  
3.2. More non-MS females than males respond to PLP peptides 
In healthy subjects and patients with neurological diseases other than MS, there was a trend in 
each group, except for GBS, for greater percentages of females than males to respond with 
SI≥2.0 or ≥3.0 to PLP peptides, as indicated by increased ratios of the percentages of female 
to male responders (Table 1). When all non-MS individuals (172 females and 174 males) 
were considered together, there was a significant increase in the percentage of females 
responding with SI≥2.0 to PLP peptides compared to males (29.1% vs 18.4%; OR=1.8[1.1–
2.7]; P=0.02). For reasons outlined in the discussion, GBS patients might be expected to give 
a different result from MS or control patients. When the results are analysed excluding the 
group of patients with GBS, the ratio of females to males reacting with SI≥2.0 to PLP 
increases to 2.02 (OR=2.4[1.3–4.4]; P=0.003). The percentages of non-MS males and females 
responding with SI≥3.0 to PLP peptides are not significantly different, whether GBS patients 
are included or excluded.  
In the MS patients, there were no significant differences between males and females for 
reactivity to PLP peptides, although the ratio of female to male responders at SI≥2.0 and 
SI≥3.0 was increased in Group 2 compared to Group 1. This may be due to the fact that 
nearly 50% of the males in Group 2 had had MS for <2 years or >20 years, compared to 26% 
of females. Since MS patients in this duration group were low responders to PLP, this may 
have artificially elevated the ratio of female to male responders.  
When all subjects (MS and non-MS) were grouped together there was increased T-cell 
reactivity to PLP in females (n=301) compared to males (n=215), which was significant both 
for SI≥2.0 (34.2% vs 21.9%; OR=1.9[1.2–2.8]; P=0.003), and SI≥3.0 (14.6% vs 8.4%; 
OR=1.9[1.1–3.3]; P=0.031). The P values for comparisons between the different cohorts of 
subjects in response to PLP are given in Table 2.  
 
Table 2. P values for comparison of reactivity to PLP and MBP between female and male MS patients 
and control subjects 
 
 
Because differences betweens females and males were observed, and since MS most 
commonly develops between the ages of 15–55 years, we therefore analysed the results 
according to the ages of the individuals (≤55 years or >55 years of age). For females with MS, 
there were no differences in the percentages in each age group responding with an SI≥2.0 to 
the PLP peptides (Fig. 2); however, in the non-MS females, a higher percentage of younger 
women (30.2%) than older women (19.2%) responded with an SI≥2.0 to the PLP peptides, 
although this difference did not reach statistical significance. There were no differences 
between the different age groups for males with or without MS (Fig. 2).  
 
Fig. 2. Effect of age on T-cell reactivity to immunodominant PLP peptides in patients with MS and 
non-MS controls. The percentages of individuals responding with SI≥2.0 in MS and non-MS groups 
for individuals aged ≤55 years or >55 years are shown. A greater proportion of non-MS females ≤55 
years of age responded with SI≥2.0 to the PLP peptides than did non-MS females >55 years of age, 
although this difference did not quite reach statistical significance.  
3.3. Females and males show no differences in reactivity to MBP 
Reactivity of healthy controls and patients with either MS or other neurological diseases to 
the whole MBP protein or to the immunodominant epitope of human MBP (MBP82-100) was 
analysed in the same way as for PLP. Except when all neurological diseases other than MS 
were grouped together, where males showed a slight increase in percentages of responses 
compared to females (P=0.042), there were no significant differences in the proportions of 
male and female subjects responding to MBP or MBP82-100 in the different groups, or when 
all female subjects were compared to all male subjects at SI≥2.0 (OR=0.8[0.6–1.2]; P=0.309) 
or SI≥3.0 (OR=1.0[0.7–1.6]; P=0.863) (Table 3). As we have observed previously [9 and 20], 
there were no significant differences in reactivity to MBP or MBP82-100 between healthy 
controls and patients with MS; however, the percentage of patients with neurological 
disorders other than MS who responded to MBP or MBP82-100 with SI≥3.0 (14.4%) was 
significantly lower than the percentage of healthy controls (29.3%; P=0.001). The P values 
for comparisons between the different cohorts of subjects in response to MBP or MBP82-100 
are given in Table 2.  
Table 3. Reactivity to MBP or MBP82-100 in patients with MS or control groups 
 
4. Discussion 
The present study confirms our previous findings of increased T-cell reactivity to 
immunodominant PLP peptides in MS patients compared to controls, and decreased T-cell 
reactivity to MBP in patients with other neurological disorders compared to healthy subjects 
[20]. Our present study also shows that, in our total group of 516 subjects, a higher proportion 
of females than males have increased T-cell reactivity to immunodominant PLP peptides. In 
particular, there is a highly significant increase in the frequency of females compared to males 
responding with SI≥2.0 to the PLP peptides. Interestingly, the female:male odds ratios for 
non-MS individuals for reactivity to immunodominant PLP peptides with SI≥2.0 are close to 
the observed MS prevalence female:male ratio for the same geographic area [33]. Our 
findings are consistent with recent work by Pelfrey et al. [23], who showed that there were 
significant differences in the responses of males and females in IFN-  responses to peptides 
of PLP in a small cohort (22 male and 22 female) of patients with MS.  
It is unclear why more women than men show increased T-cell reactivity to immunodominant 
PLP peptides. One possibility is that women might show increased T-cell reactivity to all 
antigens. There is evidence of qualitative and quantitative differences in the immune 
responses of males and females, with females having a greater Th1 response (determined by 
testing the ability of mice to respond to infection with Leishmania major, which requires a 
Th1 response) than males [37]. This difference was thought to be mediated by hormones, 
because castration of males and testosterone treatment of females modified the responses. In 
mice, after immunization, females show greater production of the Th1 cytokine IFN-  than 
males [38]. Expression of the IFN-  gene appears to be directly affected by sex hormones, as 
the sex steroid 17 beta-estradiol markedly increases activity of the IFN-  promoter in 
lymphoid cells that express the appropriate hormone receptor, and can augment the effect of 
T-cell-activating agents [39]. Furthermore, there is some evidence that females have more 
active immune responses than males, with females producing more active lymphocyte 
responses to alloantigens in the mixed lymphocyte reaction (MLR) [40], having elevated 
immunoglobulin levels compared to men [41]and an elevated CD4/CD8 T-cell ratio in 
peripheral blood [42]. Thus, there are differences between the male and female immune 
systems. However, in our study there was no female predominance in responses to MBP, 
suggesting that there may be a specific sexual dimorphism in the responses to PLP.  
Other possible explanations for a gender effect in T-cell responsiveness to PLP may be 
related to the presence of the gene for PLP on the X chromosome [43 and 44], or to the 
effects of sex hormones on expression of DM20, an alternatively spliced isoform of PLP, in 
thymic epithelial cells [45]. Gender-based differences in expression of DM20 in the thymus 
might allow shaping of the immune repertoire and differentially influence survival of PLP-
reactive T cells in males and females. Although there have been no experiments directly 
addressing the question of whether DM20 is differentially expressed in thymic epithelial cells 
of males and females, it is known that sex-hormone receptors are present on thymic cells 
[46]and that expression of myelin proteins in various tissues can be affected by the action of 
sex hormones [47].  
The only group of non-MS subjects that did not show female preponderance of T-cell 
reactivity to PLP was the group of subjects with GBS. This is of interest because GBS is a 
disorder that is reportedly more common in males than females [48]. Furthermore, GBS is 
thought to be an autoimmune disorder, and presumably patients develop GBS because they 
have T cell or antibody reactivity to an antigen important in GBS. Thus these patients might 
be expected to behave differently from MS patients and controls.  
If T-cell reactivity to PLP plays a role in the pathogenesis of MS [5 and 20], the increased 
proportion of women with increased T-cell reactivity to immunodominant PLP peptides could 
partly explain why women are more likely to develop MS than men. Clearly the presence of 
these cells in healthy normal subjects is not sufficient to cause MS. It has been shown that a 
substantial proportion of PLP-reactive cells in healthy individuals are CD45RO+memory T 
cells, suggesting that they can be activated in vivo without resulting in clinical disease [49]. In 
patients with MS, there was less difference in the proportion of female and males subjects 
with increased T-cell reactivity to PLP peptides than in controls. It might be that MS subjects, 
whether male or female, are selected by their ability to react with immunodominant PLP 
peptides. We found that some patients with MS do not show increased T-cell reactivity to 
these peptides. This could be because some subjects have an immune response to other 
antigens, or because T-cell reactivity to immunodominant PLP peptides fluctuates with time 
[5].  
It has also been shown that some autoimmune processes are protective. In MS, it has been 
suggested that disease might even result from a lack of protective autoimmunity [50]. 
Therefore, another possible significance of the difference in PLP-reactive T-cell reactivity 
between men and women is that the presence of PLP-specific T cells may assist in the 
protection from disease and that the relative lack of such cells in males might lead to the 
greater prevalence of primary progressive MS in males [51]. Such sexual dimorphism in the 
outcome of disease has been shown in rats, where adult female rats recovered better than 
males from spinal cord injury. This effect was reported to be mediated by T cells [52].  
In contrast to PLP, we found no differences between MS patients and healthy controls with 
respect to reactivity to MBP, and no differences between females and males. It has previously 
been shown that MBP-specific T cells found in healthy controls are only rarely found to be 
CD45RO+, whereas most MBP-specific T cells in MS patients are CD45RO+[53]. In addition, 
MBP-specific T cells from MS patients are reported to require less co-stimulation than MBP-
specific T cells from controls [54 and 55]. Thus, although absolute differences in MBP-
specific responses between MS and healthy controls were not observed, there may be 
qualitative differences in these responses.  
In summary we have shown that females are more likely than males to have increased T-cell 
reactivity to immunodominant PLP peptides and suggest that this difference might be relevant 
to the greater susceptibility of females to MS.  
Acknowledgements  
We acknowledge the financial support of the National Health and Medical Research Council of 
Australia, the National Multiple Sclerosis Society, USA (Grants RG 3011A1/1 to PAMcC and 
RG3190-A-1 to JMG), and MS Australia.  
References 
1. S. Lacroix-Desmazes, S.V. Kaveri, L. Mouthon, A. Ayouba, E. Malanchere, A. Coutinho et al., Self-reactive 
antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216 (1998), pp. 117–137.  
2. L. Budinger, L. Borradori, C. Yee, R. Eming, S. Ferencik, H. Grosse-Wilde et al., Identification and 
characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. 
J Clin Invest 102 (1998), pp. 2082–2089.    
3. N. Hattori, M. Kuwana, J. Kaburaki, T. Mimori, Y. Ikeda and Y. Kawakami, T cells that are autoreactive to 2-
glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 43 (2000), pp. 
65–75.  
4. N. Goebels, H. Hofstetter, S. Schmidt, C. Brunner, H. Wekerle and R. Hohlfeld, Repertoire dynamics of 
autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. 
Brain 123 (2000), pp. 508–518.  
5. M.P. Pender, P.A. Csurhes, J.M. Greer, P.D. Mowat, R.D. Henderson, K.D. Cameron et al., Surges of increased 
T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with 
multiple sclerosis than in healthy subjects. J Immunol 165 (2000), pp. 5322–5331.    
6. M.V. Tejada-Simon, J. Hong, V.M. Rivera and J.Z. Zhang, Reactivity pattern and cytokine profile of T cells 
primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 31 (2001), pp. 907–917.  
7. K. Takahashi, M.C. Honeyman and L.C. Harrison, Cytotoxic T cells to an epitope in the islet autoantigen IA-2 
are not disease specific. Clin Immunol 99 (2001), pp. 360–364.  
8. J.B. Burns, B.D. Bartholomew and S.T. Lobo, In vivo activation of myelin oligodendrocyte glycoprotein-
specific T cells in healthy control subjects. Clin Immunol 105 (2002), pp. 185–191.  
9. M.P. Pender, P.A. Csurhes, R.A. Houghten, P.A. McCombe and M.F. Good, A study of human T-cell lines 
generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. J 
Neuroimmunol 70 (1996), pp. 65–74.  
10. S.J. Seo, M.L. Fields, J.L. Buckler, A.J. Reed, L. Mandik-Nayak, S.A. Nish et al., The impact of T helper and 
T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 16 (2002), pp. 535–546.  
11. W.F. Ng, P.J. Duggan, F. Ponchel, G. Matarese, G. Lombardi, A.D. Edwards et al., Human CD4+CD25+cells: a 
naturally occurring population of regulatory T cells. Blood 98 (2001), pp. 2736–2744.  
12. B. Arnold, G. Schonrich and G. Hammerling, Multiple levels of peripheral tolerance. Immunol Today 14 
(1993), pp. 12–14.  
13. G. Lombardi, S. Sidhu, R. Batchelor et al., Anergic T cells as suppressor cells in vitro. Science 264 (1994), pp. 
1587–1589.    
14. M.P. Pender, Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ 
as a major mechanism of tolerance. Immunol Cell Biol 77 (1999), pp. 216–223.  
15. K.C. O'Connor, A. Bar-Or and D.A. Hafler, The neuroimmunology of multiple sclerosis: possible roles of T 
and B lymphocytes in immunopathogenesis. J Clin Immunol 21 (2001), pp. 81–92.  
16. S.S. Zamvil and L. Steinman, Diverse targets for intervention during inflammatory and neurodegenerative 
phases of multiple sclerosis. Neuron 38 (2003), pp. 685–688.  
17. P. Stinissen, R. Medaer and J. Raus, Myelin reactive T cells in the autoimmune pathogenesis of multiple 
sclerosis. Mult Scler 4 (1998), pp. 203–211.  
18. B.M. Keegan and J.H. Noseworthy, Multiple sclerosis. Annu Rev Med 53 (2002), pp. 285–302.  
19. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, J. Baskerville et al., The natural history of 
multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (1989), pp. 133–146.    
20. J.M. Greer, P.A. Csurhes, K.D. Cameron, P.A. McCombe, M.F. Good and M.P. Pender, Increased 
immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120 
(1997), pp. 1447–1460.  
21. M.V. Tejada-Simon, J. Hong, V.M. Rivera and J.Z. Zhang, Reactivity pattern and cytokine profile of T cells 
primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 31 (2001), pp. 907–917.  
22. J.L. Trotter, C.M. Pelfrey, A.L. Trotter, J.A. Selvidge, K.C. Gushleff, T. Mohanakumar et al., T cell 
recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of 
multiple sclerosis and control subjects. J Neuroimmunol 84 (1998), pp. 172–178.  
23. C.M. Pelfrey, A.C. Cotleur, J.C. Lee and R.A. Rudick, Sex differences in cytokine responses to myelin 
peptides in multiple sclerosis. J Neuroimmunol 130 (2002), pp. 211–223.  
24. R.P. Lisak and B. Zweiman, In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin 
basic protein in primary demyelinating diseases. N Engl J Med 297 (1977), pp. 850–853.    
25. C.J. Brinkman, W.M. Nillesen, O.R. Hommes, K.J. Lamers, B.E. de Pauw and P. Delmotte, Cell-mediated 
immunity in multiple sclerosis as determined by sensitivity of different lymphocyte populations to various brain 
tissue antigens. Ann Neurol 11 (1982), pp. 450–455.   
26. C.N. Baxevanis, G.J. Reclos, C. Servis, E. Anastasopoulos, P. Arsenis, A. Katsiyiannis et al., Peptides of 
myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 22 (1989), 
pp. 23–30.  
27. D. Johnson, D.A. Hafler, R.J. Fallis, M.B. Lees, R.O. Brady, R.H. Quarles et al., Cell-mediated immunity to 
myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J 
Neuroimmunol 13 (1986), pp. 99–108.   
28. N. Kerlero de Rosbo, R. Milo, M.B. Lees, D. Burger, C.C. Bernard and A. Ben-Nun, Reactivity to myelin 
antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte 
glycoprotein. J Clin Invest 92 (1993), pp. 2602–2608.    
29. N. Acarin, J. Rio, A.L. Fernandez, M. Tintore, I. Duran, I. Galan et al., Different antiganglioside antibody 
pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 93 (1996), pp. 99–103.    
30. B.T. Sadatipour, J.M. Greer and M.P. Pender, Increased circulating antiganglioside antibodies in primary and 
secondary progressive multiple sclerosis. Ann Neurol 44 (1998), pp. 980–983.    
31. S. Mata, F. Lolli, M. Soderstrom, F. Pinto and H. Link, Multiple sclerosis is associated with enhanced B cell 
responses to the ganglioside GD1a. Mult Scler 5 (1999), pp. 379–388.    
32. M.P. Pender, P.A. Csurhes, N.P. Wolfe, K.D. Hooper, M.F. Good, P.A. McCombe et al., Increased circulating 
T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 10 
(2003), pp. 63–66.  
33. S.R. Hammond, C. de Wytt, I.C. Maxwell, P.J. Landy, D. English, J.G. McLeod et al., The epidemiology of 
multiple sclerosis in Queensland, Australia. J Neurol Sci 80 (1987), pp. 185–204.  
34. C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, G.C. Ebers et al., New diagnostic criter 
for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983), pp. 227–231.    
35. G.E. Deibler, R.E. Martenson and M.W. Kies, Large scale preparation of myelin basic protein from central 
nervous tissue of several mammalian species. Prep Biochem Biotechnol 2 (1972), pp. 139–165.   
36. S. Markovic-Plese, H. Fukaura, J. Zhang, A. al-Sabbagh, S. Southwood, A. Sette et al., T cell recognition of 
immunodominant and cryptic proteolipid epitopes in humans. J Immunol 155 (1995), pp. 982–992.  
37. B.A. Mock and C.A. Nacy, Hormonal modulation of sex differences in resistance to Leishmania major 
systemic infections. Infect Immun 56 (1988), pp. 3316–3319.  
38. K. Huygen and K. Palfliet, Strain variation in interferon gamma production of BCG-sensitized mice challenged 
with PPD II. Importance of one major autosomal locus and additional sexual influences. Cell Immunol 85 (1984), 
pp. 75–81.  
39. H.S. Fox, B.L. Bond and T.G. Parslow, Estrogen regulates the IFN-gamma promoter. J Immunol 146 (1991), 
pp. 4362–4367.  
40. Y. Weinstein, S. Ran and S. Segal, Sex-associated differences in the regulation of immune responses 
controlled by the MHC of the mouse. J Immunol 132 (1984), pp. 656–661.  
41. M. Cutolo, A. Sulli, B. Seriolo, S. Accardo and A.T. Masi, Estrogens, the immune response and autoimmunity. 
Clin Exp Rheumatol 13 (1995), pp. 217–226.  
42. A. Amadori, R. Zamarchi, G. De Silvestro, G. Forza, G. Cavatton, G.A. Danieli et al., Genetic control of the 
CD4/CD8 T-cell ratio in humans. Nat Med 1 (1995), pp. 1279–1283.    
43. H.F. Willard and J.R. Riordan, Assignment of the gene for myelin proteolipid protein to the X chromosome: 
implications for X-linked myelin disorders. Science 230 (1985), pp. 940–942.  
44. W.B. Macklin, C.W. Campagnoni, P.L. Deininger and M.V. Gardinier, Structure and expression of the mouse 
myelin proteolipid protein gene. J Neurosci Res 18 (1987), pp. 383–394.  
45. J. Derbinski, A. Schulte, B. Kyewski and L. Klein, Promiscuousgene expression in medullary thymic epithelial 
cells mirrors the peripheral self. Nat Immunol 2 (2001), pp. 1032–1039.  
46. J. Tornwall, A.B. Carey, R.I. Fox and H.S. Fox, Estrogen in autoimmunity: expression of estrogen receptors in 
thymic and autoimmune T cells. J Gend Specif Med 2 (1999), pp. 33–40.  
47. R.C. Melcangi, V. Magnaghi, M. Galbiati and L. Martini, Steroid effects on the gene expression of peripheral 
myelin proteins. Horm Behav 40 (2001), pp. 210–214.  
48. Q. Cheng, G.X. Jiang, R. Press, M. Andersson, B. Ekstedt, M. Vrethem et al., Clinical epidemiology of 
Guillain-Barre syndrome in adults in Sweden 1996–97: a prospective study. Eur J Neurol 7 (2000), pp. 685–692.  
49. J.B. Burns, B.D. Bartholomew and S.T. Lobo, Isolation of CD45RO+, memory T cells recognizing proteolipid 
protein from neurologically normal subjects. Cell Immunol 212 (2001), pp. 44–50.  
50. M. Schwartz and J. Kipnis, Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: 
a paradigm shift. Neuroscientist 8 (2002), pp. 405–413.  
51. B. Runmarker and O. Andersen, Prognostic factors in a multiple sclerosis incidence cohort with twenty-five 
years of follow-up. Brain 116 (1993), pp. 117–134.    
52. E. Hauben, T. Mizrahi, E. Agranov and M. Schwartz, Sexual dimorphism in the spontaneous recovery from 
spinal cord injury: a gender gap in beneficial autoimmunity?. Eur J Neurosci 16 (2002), pp. 1731–1740.  
53. J. Burns, B. Bartholomew and S. Lobo, Isolation of myelin basic protein-specific T cells predominantly from 
the memory T-cell compartment in multiple sclerosis. Ann Neurol 45 (1999), pp. 33–39.  
54. C. Scholz, K.T. Patton, D.E. Anderson, G.J. Freeman and D.A. Hafler, Expansion of autoreactive T cells in 
multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 160 (1998), pp. 1532–1538.  
55. A.E. Lovett-Racke, J.L. Trotter, J. Lauber, P.J. Perrin, C.H. June and M.K. Racke, Decreased dependence of 
myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of 
activated/memory T cells. J Clin Invest 101 (1998), pp. 725–730.  
 
 
 
